Braeburn Pharmaceuticals Inc.'s subcutaneous buprenorphine formulation appears to be in good shape heading into a US FDA advisory panel, although the opioid use disorder (OUD) treatment will likely be subject to similar discussions regarding a Risk Evaluation and Mitigation Strategy (REMS) that Indivior PLCwill face the day before for its own OUD candidate.
FDA's Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee will convene in a joint session Nov....




